Stock Rating Upgrade
Of late the Value Trend Rating for Dr Reddy’S Laboratories Ltd (NYSE: RDY) improved from D to C reflecting improving fundamentals and high Appreciation Potential.
Recent Price Action
On 4/8/24, Dr Reddy’S Laboratories Ltd (NYSE: RDY) stock declined slightly by -0.08%, closing at $73.70. However, this decline was accompanied by unusually low trading volume at 53% of normal. Relative to the market the stock has been strong over the last nine months and is unchanged during the last week.
Current PriceTarget Research Rating
RDY’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
Dr Reddy’S Laboratories has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. This rating combines contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Dr Reddy’S Laboratories has a poor Appreciation Score of 27 but a slightly positive Power Rating of 69, producing the Low Neutral Value Trend Rating.
Be the first to comment